The Rise of RUO Monoclonal Antibody Use
5
Min Read
In this blog:
- How has monoclonal use changed over the years?
- Which countries are citing these products frequently?
- How does monoclonal and polyclonal use compare, and how does this help improve reproducibility?
Monoclonal RUO (Research Use Only) antibodies are increasingly used and crucial research reagents.
Today, we dive into how their use has changed over the years, with a focus on country-specific trends.
If you’re a supplier or user of monoclonal antibodies, read on to gain insight into this growing space that you should be paying attention to.
Monoclonal vs Polyclonal Research Antibody Use
Focusing on primary monoclonal antibodies, our database shows that these products have been cited over 177,000 times in 2024 alone. This demonstrates sustained research use translating into results.
Monoclonals offer numerous benefits to scientists such as reduced batch to batch variability, resulting in more reproducible results.
Our data showed that the RUO Monoclonal antibody market has been seeing increasing share compared to polyclonals. This shows that researchers are using these products more frequently in their published work.
As of 2024, the split of share between primary monoclonals and polyclonals was 64.84% to 35.16% – a big change to ten years ago.
Monoclonals vs Polyclonals: Country-by-Country Breakdown
Given the growth in this market, we were interested to drill deeper into regional trends.
When we compared monoclonal antibody citations to polyclonals we found that many countries were seeing a shift towards monoclonal use.
Most top ten countries saw a citation share split between monoclonals and polyclonals of around 64:36.
One standout was the United States. The US had the highest percentage of monoclonal citations with a split of around 68% to 32%, demonstrating increased uptake.
Although all the top ten countries saw growing monoclonal citation share, France, Italy, and South Korea stood out with a slightly larger shift to using more monoclonals in the last five years.
Interested in more granular data on monoclonal antibody use? Learn more about our market data service below.
The impact of RUO monoclonal antibodies on reproducibility
The increasing use of monoclonals can be considered a good sign for experimental reproducibility.
Polyclonals may differ from batch to batch as production is dependent upon an animals lifespan and they are comprised of a mix of immunoglobulins targeting the antigen and not a single epitope.
In contrast, when using well validated monoclonal antibodies researchers can repeat experiments from their peers and more confidently expect the same results.
It is also worth mentioning other changes in the antibody space contributing to improved reproducibility. These include recombinant antibodies and greater efforts into antibody validation.
In fact, recombinant antibody citation share has also been growing in recent years, which we commented on in our ‘Ten Years of Reagent Market Trends’ Analysis.
To get involved in the antibody validation conversation, why not consider joining the International Antibody Validation Meeting this September.
Stay ahead of industry trends with a market data subscription
Many leaders in the research reagent sector already use our market data to spot trends, develop better products and perform more effective sales and marketing campaigns.
In a particularly uncertain landscape, using quantitative data can take the risks out of product and strategy decisions, reach out to the team here to request a data demo or discuss some more.
